Smarcb1-deficient Malignancies

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-01-08
Clinical Trial Update: Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies [Phase 2]
Phase II trial evaluating Ubamatamab alone or with Cemiplimab for MUC16-expressing SMARCB1-deficient malignancies is currently recruiting.